



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 47/02, 31/135</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/30685</b> <b>(43) International Publication Date:</b> 2 June 2000 (02.06.00)
<b>(21) International Application Number:</b> PCT/CA99/01114 <b>(22) International Filing Date:</b> 18 November 1999 (18.11.99)  <b>(30) Priority Data:</b> 2,253,770 23 November 1998 (23.11.98) CA  <b>(71)(72) Applicant and Inventor:</b> SHERMAN, Bernard, Charles [CA/CA]; 50 Old Colony Road, Willowdale, Ontario M2L 2K1 (CA).		<b>(81) Designated States:</b> AU, JP, US, ZA, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION COMPRISING BUPROPION HYDROCHLORIDE  <b>(57) Abstract</b>  A pharmaceutical composition in solid dosage form comprising bupropion hydrochloride as active drug and sodium bisulfate as stabilizer.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**PHARMACEUTICAL COMPOSITION COMPRISING**  
**BUPROPION HYDROCHLORIDE**

5

**BACKGROUND OF THE INVENTION**

10

Bupropion hydrochloride is a well known antidepressant. It is sold in the United States by Glaxo Wellcome Inc. as prompt release tablets under the tradename WELLBUTRIN® and sustained release tablets under the tradename, WELLBUTRIN SR®.

15

Bupropion hydrochloride is known to be relatively unstable, such that tablets containing bupropion hydrochloride will degrade at an unacceptably high rate unless the tablets are made by a method or using ingredients which result in improved stability.

20

U.S. patent 5,358,970 discloses stabilization of bupropion hydrochloride by including in the tablets a stabilizer. The specific stabilizers disclosed are L-cysteine hydrochloride, glycine hydrochloride, ascorbic acid, malic acid, sodium metabisulfite, isoascorbic acid, citric acid, and L-cysteine hydrochloride. L-cysteine hydrochloride and glycerin hydrochloride are said to be most preferred. All of the examples in U.S. patent 5,358,970 use L-cysteine hydrochloride or glycine hydrochloride as the stabilizer, and, in each

25

example, the process of manufacture includes the steps of dissolving the stabilizer in water and alcohol, using the solution to granulate the bupropion hydrochloride and other ingredients, and then drying the wet mass.

30

Such a process has the disadvantage of requiring the use of water and alcohol, and requiring the steps of preparing the solution, using the solution to granulate powder, and drying the wet granulated material.

The object of the present invention is to enable stabilization of compositions comprising bupropion hydrochloride by using a stabilizer other than that disclosed in U.S. patent 5,358,970.

5

### DESCRIPTION OF THE INVENTION

10

It has been found that the inclusion of sodium bisulfate as an ingredient in solid compositions comprising bupropion hydrochloride results in improved stability, even if the ingredients are mixed in dry form without use of water, alcohol or any other solvent.

15

Compositions within the scope of the present invention will thus be solid compositions (such as tablets or capsules) comprising bupropion hydrochloride and sodium bisulfate. Sodium bisulfate is available as both anhydrous and monohydrate. Either form may be used in the present invention.

20

A preferred ratio of sodium bisulfate to bupropion hydrochloride by weight is from about 1 to about 20 parts sodium bisulfate per 100 parts bupropion hydrochloride. A more preferred ratio is from about 2 to about 10 parts sodium bisulfate per 100 parts bupropion hydrochloride. The most preferred ratio is about 5 parts sodium bisulfate per 100 parts bupropion hydrochloride.

25

Solid compositions in the form of tablets, for example, can be made simply by mixing bupropion hydrochloride and sodium bisulfate, along with other usual tableting ingredients, and then compressing the mixture into tablets on a tablet process.

30

5 The other usual tableting ingredients may include and will preferably include a binder, such as, for example, microcrystalline cellulose or hydroxypropyl methylcellulose; a lubricant such as, for example, magnesium stearate, zinc stearate, or stearic acid, and a glidant such as, for example, colloidal silicon dioxide.

10 If the flowability of the mixed powder is not adequate for direct compression into tablets, the mixture may be compacted, following which the compacted material will be ground up into free flowing granules. These granules will then be compressed into tablets on a tablet press.

The following examples are representative of the invention, but not limiting.

15 Ingredients were mixed in proportions as follows:

	<u>Ex. 1</u>	<u>Ex. 2</u>	<u>Ex. 3</u>	<u>Ex. 4</u>	<u>Ex. 5</u>
Bupropion hydrochloride	100.	100.	100	100	100.
Microcrystalline Cellulose	98.	96.	94.	90.	82.
20 Sodium Bisulfate, Monohydrate	0	2.	4.	8.	16.
Zinc Stearate	1.6	1.6	1.6	1.6	1.6
Colloidal silicon dioxide	<u>0.4</u>	<u>0.4</u>	<u>0.4</u>	<u>0.4</u>	<u>0.4</u>
	200.	200.	200.	200	200.

25 In each case, the powder mixture was compacted, the compacted material was ground up into granules, and the granules were recompressed on a tablet press into tablets of net weight 200 mg each. Each tablet thus contained 100 mg of bupropion hydrochloride, and the amount of sodium bisulfate per tablet was nil in example 1, 2 mg in example 2, 4 mg in example 3, and 8 mg in example 4, and 16 mg in example 5.

The tablets of all 5 examples were stored for a period of one week at 50°C, this condition of elevated temperature being known to cause accelerated degradation of bupropion hydrochloride.

5

At the end of the one week period, the tablets were analyzed to determine the total amount of degradation products as a percentage of the initial amount of bupropion hydrochloride. The total amount of degradation products was found to be over 25% for example 1 (which uses no sodium bisulfate), but only 2.89% for example 2, 0.26% for example 3, and 0.11% for examples 4 and 5.

10

It thus can be seen that the inclusion of sodium bisulfate in the tablets decreases the rate of degradation. Furthermore, the rate of degradation decreases with increased amount of sodium bicarbonate. In example 3, which comprises 4 parts sodium bisulfate per 100 parts bupropion hydrochloride, the rate of degradation is acceptably low, and it appears that there is thus little to be gained by using substantially above this level of sodium bisulfate. It is thus concluded that the most preferred ratio of sodium bisulfate to bupropion hydrochloride is about 5 parts sodium bisulfate to 100 parts bupropion hydrochloride.

15

20

25

30

WHAT IS CLAIMED IS:

- 5           1.     A pharmaceutical composition in solid form comprising bupropion hydrochloride and sodium bisulfate.
2.     A composition of claim 1, comprising by weight from about 1 to about 20 parts sodium bisulfate per 100 parts bupropion hydrochloride.
- 10       3.     A composition as in claim 2, comprising by weight from about 2 to about 10 parts sodium bisulfate per 100 parts bupropion hydrochloride.
4.     A composition as in claim 3, comprising by weight about 5 parts sodium bisulfate per 100 parts bupropion hydrochloride.
- 15       5.     A composition as in any of claims 1 to 4 in the form of a tablet.

20

25

30

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/CA 99/01114

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/02 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 358 979 A (MICHAEL D. RUFF, ET AL.) 25 October 1994 (1994-10-25) cited in the application the whole document	1-5
P,A	WO 99 33456 A (AMERICAN HOME PRODUCTS) 8 July 1999 (1999-07-08) the whole document	1-5

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

16 February 2000

Date of mailing of the international search report

28/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/01114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5358979 A	25-10-1994	AT 151092 T	15-04-1997
		AU 649297 B	19-05-1994
		DE 69125505 D	07-05-1997
		EP 0646150 A	05-04-1995
		JP 6503079 T	07-04-1994
		NO 932163 A	11-06-1993
		AU 9040891 A	08-07-1992
		CA 2098280 A	14-06-1992
		WO 9210530 A	25-06-1992
		FI 932689 A	11-06-1993
		IL 100358 A	31-10-1995
WO 9933456 A	08-07-1999	US 5968553 A	19-10-1999
		AU 2015399 A	19-07-1999